European Journal of Immunology,
Год журнала:
2023,
Номер
53(12)
Опубликована: Авг. 23, 2023
Knowledge
about
early
immunity
to
SARS-CoV-2
variants
of
concern
mainly
comes
from
the
analysis
human
blood.
Such
data
provide
limited
information
host
responses
at
site
infection
and
largely
miss
initial
events.
To
gain
insights
into
compartmentalization
dynamics
different
variants,
we
utilized
angiotensin
converting
enzyme
2
(hACE2)
transgenic
mice
tracked
immune
changes
during
first
days
after
by
RNAseq,
multiplex
assays,
flow
cytometry.
Viral
challenge
led
divergent
viral
loads
in
lungs,
distinct
inflammatory
patterns,
innate
cell
accumulation
response
ancestral
SARS-CoV-2,
Beta
(B.1.351)
Delta
(B.1.617.2)
variant
(VOC).
Compared
other
with
VOC
spread
promptly
leading
increased
responses.
SARS-CoV-2-specific
antibodies
T
cells
developed
within
7
postinfection
were
required
reduce
replication.
Our
studies
show
that
VOCs
differentially
trigger
transcriptional
profiles
inflammation.
This
contributes
basic
understanding
immediately
postexposure
is
relevant
for
developing
pan-VOC
interventions
including
prophylactic
vaccines.
Communications Biology,
Год журнала:
2025,
Номер
8(1)
Опубликована: Янв. 15, 2025
Abstract
We
have
assessed
antiviral
activity
and
induction
of
protective
immunity
fusion-inhibitory
lipopeptides
derived
from
the
C-terminal
heptad-repeat
domain
SARS-CoV-2
spike
glycoprotein
in
transgenic
mice
expressing
human
ACE2
(K18-hACE2).
The
block
infection
cell
lines
lung-derived
organotypic
cultures.
Intranasal
administration
allows
maintenance
homeostatic
transcriptomic
immune
profile
lungs,
prevents
body-weight
loss,
decreases
viral
load
shedding,
protects
death
caused
by
variants.
Prolonged
high-dose
has
neither
adverse
effects
nor
impairs
peptide
efficacy
subsequent
challenges.
peptide-protected
develop
cross-reactive
neutralizing
antibodies
against
both
used
for
initial
recently
circulating
variants,
are
completely
protected
a
second
lethal
infection,
suggesting
that
they
developed
SARS-CoV-2-specific
immunity.
This
strategy
provides
an
additional
approach
global
effort
COVID-19
may
contribute
to
development
rapid
responses
emerging
pathogenic
viruses.
Journal of Virology,
Год журнала:
2023,
Номер
97(2)
Опубликована: Янв. 23, 2023
Coronavirus
disease
2019
(COVID-19),
which
is
caused
by
the
novel
coronavirus
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
most
emerging
infectious
in
current
century.
The
discovery
of
SARS-CoV-2-related
coronaviruses
(SARSr-CoV-2)
bats
and
pangolins
South
Asian
countries
indicates
that
SARS-CoV-2
likely
originated
from
wildlife.
To
date,
two
SARSr-CoV-2
strains
have
been
isolated
seized
Guangxi
Guangdong
customs
agency
China,
respectively.
However,
it
remains
unclear
whether
these
viruses
cause
animal
models
they
pose
a
transmission
risk
to
humans.
In
this
study,
we
investigated
biological
features
strain
smuggled
Malayan
pangolin
(Manis
javanica)
captured
agency,
termed
MpCoV-GX,
terms
receptor
usage,
cell
tropism,
pathogenicity
wild-type
BALB/c
mice,
human
angiotensin-converting
enzyme
(ACE2)-transgenic
ACE2
knock-in
mice.
We
found
MpCoV-GX
can
utilize
humans,
pangolins,
civets,
bats,
pigs,
mice
for
entry
infect
lines
derived
monkeys,
minks,
pigs.
virus
could
three
mouse
but
showed
limited
pathogenicity,
with
mild
peribronchial
perivascular
inflammatory
infiltration
observed
lungs.
Our
results
suggest
has
potential
interspecies
infection,
its
Future
surveillance
among
wildlife
hosts
needed
monitor
variants
may
higher
spillover
risk.
IMPORTANCE
SARS-CoV-2,
spilled
over
wildlife,
third
highly
pathogenic
coronavirus.
Being
transmissible,
perpetuating
pandemic
continuously
posing
threat
global
public
health.
Several
identified
since
outbreak.
It
therefore
important
assess
their
crossing
species
barriers
better
understanding
future
emergence.
work,
pangolin,
named
MpCoV-GX.
7
variety
mammalian
species.
expressing
without
causing
disease.
These
findings
cross-species
highlight
need
further
other
hosts.
The
COVID-19
pandemic,
caused
by
SARS-CoV-2,
is
still
significantly
impacting
health
care
systems
around
the
globe.
Refined
animal
models
are
needed
to
study
SARS-CoV-2
pathogenicity
as
well
efficacy
of
vaccines
and
therapeutics.
SARS-CoV-2
variants,
with
the
threat
of
increased
transmissibility,
infectivity,
and
immune
escape,
continue
to
emerge
as
COVID-19
pandemic
progresses.
Detailing
pathogenesis
disease
caused
by
such
Delta,
is
essential
better
understand
clinical
emerging
variants
associated
disease.
Viruses,
Год журнала:
2023,
Номер
15(4), С. 999 - 999
Опубликована: Апрель 19, 2023
Since
December
2019,
the
world
has
been
experiencing
COVID-19
pandemic
caused
by
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
and
we
now
face
emergence
of
several
variants.
We
aimed
to
assess
differences
between
wild-type
(Wt)
(Wuhan)
strain
P.1
(Gamma)
Delta
variants
using
infected
K18-hACE2
mice.
The
clinical
manifestations,
behavior,
virus
load,
pulmonary
capacity,
histopathological
alterations
were
analyzed.
P.1-infected
mice
showed
weight
loss
more
manifestations
than
Wt
Delta-infected
capacity
was
reduced
in
compared
other
groups.
Pulmonary
histological
findings
demonstrated
that
a
aggressive
disease
generated
virus.
quantification
SARS-CoV-2
viral
copies
varied
greatly
among
although
it
higher
on
day
death.
Our
data
revealed
with
variant
develop
infectious
those
variants,
despite
significant
heterogeneity
Communications Biology,
Год журнала:
2024,
Номер
7(1)
Опубликована: Фев. 16, 2024
Abstract
The
persistence
of
SARS-CoV-2
despite
the
development
vaccines
and
a
degree
herd
immunity
is
partly
due
to
viral
evolution
reducing
vaccine
treatment
efficacy.
Serial
infections
wild-type
(WT)
in
Balb/c
mice
yield
mouse-adapted
strains
with
greater
infectivity
mortality.
We
investigate
if
passaging
unmodified
B.1.351
(Beta)
B.1.617.2
(Delta)
20
times
K18-ACE2
mice,
expressing
human
ACE2
receptor,
BSL-3
laboratory
without
selective
pressures,
drives
health-relevant
lineage-dependent.
Late-passage
virus
causes
more
severe
disease,
at
organism
lung
tissue
scales,
late-passage
Delta
demonstrating
antibody
resistance
interferon
suppression.
This
co-occurs
de
novo
spike
S371F
mutation,
linked
both
traits.
S371F,
an
Omicron-characteristic
co-inherited
E1182G
per
Nanopore
sequencing,
existing
different
within-sample
variants
others.
Both
are
mammalian
GOLGA7
ZDHHC5
interactions,
which
mediate
viral-cell
entry
antiviral
response.
study
demonstrates
SARS-CoV-2’s
tendency
evolve
phenotypic
consequences,
its
varying
by
lineage,
suggests
non-dominant
quasi-species
contribution.
PLoS ONE,
Год журнала:
2025,
Номер
20(2), С. e0314518 - e0314518
Опубликована: Фев. 21, 2025
Introduction
With
the
emergence
of
new
SARS-CoV-2
variants
has
come
significant
variations
in
disease
manifestation,
severity,
and
duration
non-hospitalized
infected
patients.
To
characterize
symptom
patterns
risk
factors
associated
with
severity
duration,
COVID-19
influenza-like
illness
(ILI)
outpatients
their
contacts
were
enrolled
at
two
sites
United
States
America
one
site
Thailand.
Methods
infection
was
confirmed
enrollment
a
positive
antigen
or
PCR
test.
Baseline
demographics
medical
histories
collected
from
participants
daily
self-reported
questionnaires
obtained
to
assess
duration.
Risk
determined
by
multivariate
logistic
regression
Cox
proportional
hazards
model.
Results
Two
hundred
forty
meeting
eligibility
criteria
enrolled,
including
174
cases
(9%
Delta
90%
Omicron),
33
ILI
cases,
34
healthy
contacts.
had
shorter
median
9.0
(95%
CI,
8.0–11.0)
days
than
participants.
Infection
variant
resulted
longer
alleviation
period
compared
Omicron
variant.
The
most
commonly
reported
symptoms
among
nasal
chest/respiratory
domains
FLU-PRO
Plus.
Participants
more
overall,
significantly
affecting
eyes
senses
reported.
55%
SARS-CoV-2-positive
reached
negative
N1
Ct
value
day
14
study
time
point.
No
for
moderate
severe
identified
this
outpatient
cohort.
Male
sex
Conclusion
Symptom
manifestation
varied
variants.
Few
increased
Proceedings of the National Academy of Sciences,
Год журнала:
2025,
Номер
122(12)
Опубликована: Март 18, 2025
Platelets,
known
for
maintaining
blood
balance,
also
participate
in
antimicrobial
defense.
Upon
severeacute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection,
platelets
become
hyperactivated,
releasing
molecules
such
as
cytokines,
granule
contents,
and
bioactive
lipids.
The
key
effector
biolipids
produced
by
include
12-hydroxyeicosatetraenoic
acid
(12-HETE)
12-hydroxyeicosatrienoic
(12-HETrE),
12-lipoxygenase
(12-LOX),
prostaglandins
thromboxane,
cyclooxygenase-1.
While
prostaglandin
E2
thromboxane
B2
were
previously
associated
with
lung
inflammation
severe
COVID-19,
the
role
of
platelet
12-LOX
SARS-CoV-2
infection
remains
unclear.
Using
mice
deficient
platelets’
12-LOX,
we
report
that
resulted
higher
characterized
histopathological
tissue
analysis,
increased
leukocyte
infiltrates,
cytokine
production
relative
to
wild-type
mice.
In
addition,
distinct
transcriptomic
changes,
including
alterations
NOD-like
receptor
(NLR)
family
pyrin
domain-containing
1
(NLRP1)
inflammasome-related
gene
expression,
observed.
Mass
spectrometry
lipidomic
analysis
12-LOX-deficient-infected
revealed
significant
changes
lipid
content,
reduced
levels
12-HETrE
inversely
correlated
disease
severity.
Finally,
deficiency
was
morbidity
lower
survival
rates
wild
type
(WT)
Overall,
this
study
highlights
complex
interplay
between
12-LOX-related
metabolism
inflammatory
responses
during
infection.
findings
provide
valuable
insights
into
potential
therapeutic
targets
aimed
at
mitigating
outcomes,
emphasizing
pivotal
enzymes
host
response
viral
infections.
Healthcare,
Год журнала:
2023,
Номер
11(8), С. 1183 - 1183
Опубликована: Апрель 20, 2023
Three
years
since
the
COVID-19
pandemic
started,
there
is
still
little
information
about
patients
with
chronic
medical
conditions,
such
as
cardiovascular
diseases
(CVDs),
who
become
infected
SARS-CoV-2.
A
retrospective
analysis
was
performed
to
evaluate
impact
of
on
comorbidities
hospitalized
positive
RT-PCR
results
for
SARS-CoV-2
during
highest
peaks
first
three
waves:
April
2020,
October
and
November
2021.
The
primary
outcome
in-hospital
mortality;
secondary
outcomes
were
length
hospitalization
required
mechanical
ventilation
assess
disease
severity.
Data
extracted
from
hospital
electronic
database
system:
680
eligible
cases
identified
out
2919
patients.
Mortality
in
wave
3
(31.9%)
compared
previous
waves
(13.6%
25.8%).
Hospitalization
also
significantly
longer
(11.58
±
5.34
vs.
8.94
4.74
10.19
5.06;
p
<
0.001),
so
need
(21.7%
8.2%
9%;
0.001).
Older
age
male
gender
confirmed
highly
significant
predictors
unfavorable
outcomes.
Ischemic
heart
worsened
odds
patients’
survival
irrespective
(Breslow–Day
test,
=
0.387),
a
marginally
Mantel–Haenszel
common
estimate
risk:
OR
1.604,
95%
(0.996;
2.586).
worse
could
have
been
influenced
by
combination
factors:
low
percentage
vaccinations
Romanian
population,
more
virulent
delta
strain,
attrition
care
provided
these
CVDs.